Decipher genomic classifier (DGC) of early prostate cancer (EPC), and underlying transcriptomic profile (TP): American (Am) versus non-American (NA). | Oral Abstract | Thursday, February 13 | 8:00 AM – 9:40 AM PT | Shuang Zhao, M.D. | Level 3, Ballroom & Live Stream | |
Decipher genomic classifier (DGC) of early prostate cancer (EPC), and underlying transcriptomic profile (TP): American (Am) versus non-American (NA). | Poster #L10 | Thursday, February 13 | 11:25 AM – 12:45 PM PT | Daniel Keizman, M.D. | Level 1, West Hall & On Demand | |
Characterizing the activity of inflammasome genes and their association with oncological outcomes in prostate cancer. | Poster #L6 | Thursday, February 13 | 11:25 AM – 12:45 PM PT | Alireza Ghoreifi, M.D. | Level 1, West Hall & On Demand | |
Tumor necrosis factor alpha signaling activity and NCCN risk, adverse pathology, and progression during active surveillance in prostate cancer. | Poster #L11 | Thursday, February 13 | 11:25 AM – 12:45 PM PT | Conor Driscoll, M.D. | Level 1, West Hall & On Demand | |
Assessment of PARP1 mRNA expression as prognostic of aggressive pathology and adverse outcomes, and as predictor of response to PARP inhibition in castration-sensitive prostate cancer. | Poster #F6 | Thursday, February 13 | 11:25 AM – 12:45 PM PT | Emmanuel S. Antonarakis, M.D. | Level 1, West Hall & On Demand | |
Androgen receptor activity in biopsy specimens at initial diagnosis of prostate cancer and correlation with outcomes and treatment response. | Poster #L5 | Thursday, February 13 | 11:25 AM – 12:45 PM PT | Nicole Handa, M.D. | Level 1, West Hall & On Demand | |
Comparison of digital pathology AI models, genomics classifier, and clinical variables in predicting progression free survival in TCGA prostate data set. | Poster #H35 | Thursday, February 13 | 11:25 AM – 12:45 PM PT | Aidan McLoughlin | Level 1, West Hall & On Demand | |
Risk stratification using the Decipher 22-gene genomic classifier (GC) and digital pathology artificial intelligence (DPAI) in nearly 10,000 localized prostate cancer patients. | Poster: #L4 | Thursday, February 13 | 11:25 AM – 12:45 PM PT | Daniel E. Spratt, M.D. | Level 1, West Hall & On Demand | |
PORTOS gene signature as a predictor of risk of adverse events after dose-escalated vs. lower-dose prostate radiation therapy in NRG/RTOG 0126. | Poster #K5 | Thursday, February 13 | 11:25 AM – 12:45 PM PT | Karen E. Hoffman, M.D., MHSc, MPH | Level 1, West Hall & On Demand | |
Decipher risk stratification of radiorecurrent prostate cancer: Correlative analysis of the F-SHARP trial of salvage reirradiation. | Poster #L15 | Thursday, February 13 | 11:25 AM – 12:45 PM PT | Abhishek A Solanki, M.D., M.S. | Level 1, West Hall & On Demand | |
Decipher score as a predictor of response to treatment intensification in the NRG Oncology-RTOG 0534 (SPPORT) phase III randomized post-prostatectomy salvage radiotherapy trial. | Poster #K29 | Thursday, February 13 | 11:25 AM – 12:45 PM PT | Alan Pollack, M.D., Ph.D. | Level 1, West Hall & On Demand | |
Evaluating associations between genomic classifier and digital pathology–based multi-modal AI biomarkers in oligometastatic castration-sensitive prostate cancer. | Poster #G4 | Thursday, February 13 | 11:25 AM – 12:45 PM PT | Philip A. Sutera, M.D. | Level 1, West Hall & On Demand | |
Grade and volume progression and its association with the Decipher genomic classifier using patients enrolled in a prospective active surveillance protocol. | Poster #H3 | Thursday, February 13 | 11:25 AM – 12:45 PM PT | David J Lee, M.D., B.A. | Level 1, West Hall & On Demand | |
Gene expression signatures in biopsy cores as predictors of coexisting higher-grade disease in Gleason group 1 prostate cancer: Results from the Miami MAST prospective clinical trial. | Poster #G12 | Thursday, February 13 | 11:25 AM – 12:45 PM PT | David J Lee, M.D., B.A. | Level 1, West Hall & On Demand | |
Impact of gene expression signatures of immune infiltration on response to sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guerin in high-risk non-muscle-invasive bladder cancer. | Poster #G28 | Friday, February 14 | – | Ian M. McElree, B.S., M.S. (1st author is Vignesh Packiam) | Level 1, West Hall & On Demand | |
A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer. | Poster #G27 | Friday, February 14 | – | Yair Lotan, M.D. | Level 1, West Hall & On Demand | |
The estrogen response pathway as a putative predictive biomarker of neoadjuvant pembrolizumab benefit in patients with muscle-invasive bladder carcinoma (MIBC). | Poster #H7 | Friday, February 14 | – | Valentina Tateo, M.D. | Level 1, West Hall & On Demand | |